Cue Health has received a $28m federal contract for the development of Flu A/B, RSV and Covid-19 molecular multiplex tests for both point-of-care (POC) and over-the-counter applications.

The contract has been awarded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The test is being developed to identify and distinguish the four viruses, delivering results in approximately 25 minutes.

Cue Health has also submitted an application to the US Food and Drug Administration (FDA), seeking emergency use authorisation (EUA) for its Cue Flu + COVID-19 Molecular Test.

Additionally, the company has applied to the FDA for the De Novo classification of the Cue RSV Molecular Test, seeking authorisation.

In March this year, the corporation secured EUA from the FDA for the Cue Mpox (Monkeypox) Molecular Test, which can be used at POC at any CLIA-waived facility.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Cue Health chairman and CEO Ayub Khattak said: “We expect this test will arm individuals and their providers with actionable information that can reduce community spread, increase the efficacy of treatment and help lead to better health outcomes.”

In 2020, Cue secured a contract from BARDA to boost the development, validation and FDA approval of its Covid-19 test.

It is claimed to be the first molecular test to obtain FDA EUA for over-the-counter and at-home use without a prescription.

Recently, the corporation secured De Novo authorisation from the FDA for the same Covid-19 test called the Cue Covid-19 Molecular Test. All molecular tests of the company run on the Cue Health Monitoring System.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact